Plain-English translation of NCT07477119 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a personalized approach to dosing linezolid—a strong antibiotic used to treat drug-resistant tuberculosis—can help patients tolerate the medication better. Linezolid is part of a newer, shorter 6-month treatment regimen, but it can cause serious side effects like nerve damage and blood problems. The study will compare patients who receive the standard dose with regular monitoring to patients whose doses are adjusted based on blood test results.
Drug-resistant tuberculosis is a serious global health problem, and while this newer medication combination is effective, many patients have to stop taking it because of severe side effects. Researchers believe that tailoring each patient's dose based on blood tests—rather than giving everyone the same dose—might reduce these harmful effects while keeping the treatment working.
You likely qualify if…
You likely don't qualify if…
You will receive tuberculosis treatment for 6 months and have regular blood tests to measure the medication levels in your body. Depending on which group you're in, your dose may stay the same or be adjusted based on these blood test results. During the first month, you'll have weekly blood draws (4 samples), then monthly samples for the remaining 5 months, plus extra samples if side effects develop. The entire study lasts 6 months.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Guinea